The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase
Diabetes · 01.01.2023 · 72 (1) · 126-134
DOI: 10.2337/db22-0221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 18.10.2022. Verfasst von Seyed Amirhossein Tabatabaei Dakhili und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Antipsychotic Agents, Diabetes Mellitus, Type 2, Hyperglycemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CIHR, Institute of Nutrition, Metabolism and Diabetes.
Abstract (Originalsprache)
Despite significant progress in understanding the pathogenesis of type 2 diabetes (T2D), the condition remains difficult to manage. Hence, new therapeutic options targeting unique mechanisms of action are required. We have previously observed that elevated skeletal muscle succinyl CoA:3-ketoacid CoA transferase (SCOT) activity, the rate-limiting enzyme of ketone oxidation, contributes to the hyperglycemia characterizing obesity and T2D. Moreover, we identified that the typical antipsychotic agent pimozide is a SCOT inhibitor that can alleviate obesity-induced hyperglycemia. We now extend those observations here, using computer-assisted in silico modeling and in vivo pharmacology studies that highlight SCOT as a noncanonical target shared among the diphenylbutylpiperidine (DPBP) drug class, which includes penfluridol and fluspirilene. All three DPBPs tested (pimozide, penfluridol, and fluspirilene) improved glycemia in obese mice. While the canonical target of the DPBPs is the dopamine 2 receptor, studies in obese mice demonstrated that acute or chronic treatment with a structurally unrelated antipsychotic dopamine 2 receptor antagonist, lurasidone, was devoid of glucose-lowering actions. We further observed that the DPBPs improved glycemia in a SCOT-dependent manner in skeletal muscle, suggesting that this older class of antipsychotic agents may have utility in being repurposed for the treatment of T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
- Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
- Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
- Division of Molecular Medicine, Department of Medicine, Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN.
- Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
ORCID-Profile: John R Ussher
Förderung
- CIHR
- Institute of Nutrition, Metabolism and Diabetes
Zitieren
APA
Tabatabaei Dakhili, S. A., Greenwell, A. A., Yang, K., Abou Farraj, R., Saed, C. T., Gopal, K., Chan, J. S. F., Chahade, J. J., Eaton, F., Lee, C., Velázquez-Martínez, C. A., Crawford, P. A., Glover, J. N. M., Al Batran, R., & Ussher, J. R. (2023). The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes, 72(1), 126-134. https://doi.org/10.2337/db22-0221
Vancouver
Tabatabaei Dakhili SA, Greenwell AA, Yang K, Abou Farraj R, Saed CT, Gopal K, et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes. 2023;72(1):126-134. doi:10.2337/db22-0221
BibTeX
@article{TabatabaeiDakhili2023,
author = {Tabatabaei Dakhili, Seyed Amirhossein and Greenwell, Amanda A and Yang, Kunyan and Abou Farraj, Rabih and Saed, Christina T and Gopal, Keshav and Chan, Jordan S F and Chahade, Jadin J and Eaton, Farah and Lee, Crystal and Velázquez-Martínez, Carlos A and Crawford, Peter A and Glover, J N Mark and Al Batran, Rami and Ussher, John R},
title = {The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase},
journal = {Diabetes},
year = {2023},
volume = {72},
number = {1},
pages = {126--134},
doi = {10.2337/db22-0221}
}
EUVIMED